Page last updated: 2024-11-04

gatifloxacin and Brucellosis

gatifloxacin has been researched along with Brucellosis in 1 studies

Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.

Brucellosis: Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atkins, HS1
Spencer, S1
Brew, SD1
Laws, TR1
Thirlwall, RE1
MacMillan, AP1
Brooks, TJ1
Simpson, AJ1

Other Studies

1 other study available for gatifloxacin and Brucellosis

ArticleYear
Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection.
    International journal of antimicrobial agents, 2009, Volume: 34, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Brucella melitensis; Brucello

2009